BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Deals reach a record $213.5B, as M&As in 2021 struggle
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Deals reach a record $213.5B, as M&As in 2021 struggle
Jan. 12, 2022
By
Karen Carey
No Comments
The value of biopharma deals in 2021 rose above the prior year’s record by about 8%, thanks to an increasing number of high-money transactions. Mergers and acquisitions, however, fell 32% below 2020 as the industry gravitated more toward financings.
BioWorld
Analysis and data insight
Deals and M&A